Werewolf Therapeutics files merger registration as HOWL stock faces dilution

Published on 10/16/2026 at 03:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Werewolf filed an S-4 on September 22, 2026 for a USD 500.0 million Ambros merger. HOWL stock faces a USD 150.0 million PIPE and 6.40 percent ownership.

Corporate milestones ahead

The proposed transaction assigns Ambros an equity value of USD 500.0 million in the September 22, 2026 filing.
Existing Werewolf holders are projected to own 6.40 percent of the combined company after the transaction.
Werewolf Therapeutics is scheduled to report its next earnings on November 5, 2026.

HOWL, US95075A1079, Illustration mit AI erstellt.

Werewolf Therapeutics (US95075A1079) filed a registration statement on September 22, 2026 for its proposed merger with Ambros Therapeutics, assigning Ambros an equity value of USD 500.0 million and Werewolf an equity value of USD 47.5 million, according to the Werewolf Therapeutics filing. HOWL stock is tied to a transaction that still requires shareholder and Nasdaq approvals.

Merger financing totals USD 150.0 million

The proposed combination includes a concurrent private placement of USD 150.0 million. The filing says the financing is intended to close immediately before the merger and depends on specified conditions, including a minimum aggregate proceeds threshold of USD 100.0 million, according to the SEC.

What does the ownership split mean?

The filing projects that existing Werewolf equity holders outside the financing would own approximately 6.40 percent of the combined company after closing. Ambros equity holders would own approximately 72.00 percent, while PIPE investors would hold approximately 21.60 percent, making the ownership shift a central issue for current shareholders.

Three merger milestones

On August 21, 2026, Werewolf and Ambros signed the merger agreement and the USD 150.0 million subscription agreement, according to the SEC filing. On September 22, 2026, Werewolf submitted the Form S-4 registration statement, which also described the USD 500.0 million Ambros valuation. On October 1, 2026, Cooley listed the transaction as a USD 550.0 million merger with concurrent USD 150.0 million financing, according to Cooley.

Next reporting date is November 5

Investing.com lists November 5, 2026 as Werewolf Therapeutics' next earnings date. The report could provide a financial checkpoint before shareholders assess the proposed change of control and the planned name change to Ambros Therapeutics.

Approvals remain the key condition

The S-4 requires approval of the stock issuance, change of control, reverse stock split and name change proposals. Nasdaq must also confirm listing approval for the combined company, which is expected to use the symbol AMBX after completion.